Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,068 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Fibrosis Clear all
Not yet recruiting Not applicable Interventional

Nutrition Supplement for Cystic Fibrosis

NCT07163078
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
Common form supplementation, Uncommon nutrient supplementation
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

NCT05453578
View directory record Official record
Conditions
Bacterial Disease Carrier, Cystic Fibrosis
Interventions
Placebo, WRAIR-PAM-CF1
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 4, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00332215
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Sodium Pyruvate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 30, 2008 · Synced Sep 4, 2026, 5:32 AM EDT
Completed No phase listed Observational

The Role of Bacteria and Genetic Variations in Cystic Fibrosis

NCT00043225
View directory record Official record
Conditions
Psuedomas Infection, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
9 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
4
States / cities
Bethesda, Maryland • Seattle, Washington • Madison, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)

NCT01462006
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Diffuse Parenchymal Lung Disease, Interstitial Lung Disease
Interventions
sirolimus, Placebo
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 4, 2026, 5:32 AM EDT
Completed No phase listed Observational

Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary Exacerbations

NCT04354038
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

NCT01766817
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BMS-986020, Placebo matching with BMS-986020
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years to 90 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Effect of Simvastatin on CF Airway Inflammation

NCT00255242
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Simvastatin treatment for 28 days
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
10 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2009 · Synced Sep 4, 2026, 5:32 AM EDT
Active, not recruiting Not applicable Interventional

Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis

NCT02848625
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Yoga
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

SD Cystic Fibrosis Study

NCT00605761
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SB656933
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Palo Alto, California • Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Digitoxin to Treat Cystic Fibrosis

NCT00782288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
digitoxin, placebo
Drug · Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 4, 2026, 5:32 AM EDT
Completed No phase listed Observational

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

NCT00368446
View directory record Official record
Conditions
Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis

NCT02504827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ceftazidime/avibactam
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

NCT02951182
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ, IVA, VX-440, Matched Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 4, 2026, 5:32 AM EDT
Suspended Not applicable Interventional

A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis

NCT00005110
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Salmeterol, Albuterol
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

NCT03691779
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

NCT00352482
View directory record Official record
Conditions
Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions
Sildenafil (50 mg)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 4, 2026, 5:32 AM EDT
Completed No phase listed Observational

Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung

NCT01805713
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
6 Months and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Phase II Study of Growth Hormone in Children With Cystic Fibrosis

NCT00016445
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
growth hormone
Drug
Lead sponsor
University of Utah
Other
Eligibility
5 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
9
States / cities
Phoenix, Arizona • Orange, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2008 · Synced Sep 4, 2026, 5:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Sep 4, 2026, 5:32 AM EDT
Terminated Phase 4 Interventional Results available

Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT03717012
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib, Pulmonary rehabilitation program
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Loma Linda, California • Danbury, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 4, 2026, 5:32 AM EDT
Withdrawn No phase listed Observational

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

NCT00977158
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Throat Swab
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
1 Day to 3 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions
BCG TICE Vaccine
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 4, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Letermovir for CMV Prevention After Lung Transplantation

NCT05041426
View directory record Official record
Conditions
Lung Transplant, CMV
Interventions
Letermovir, Valganciclovir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 4, 2026, 5:32 AM EDT